14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 28, 2025
CLSD vs CHEK: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
CHEK Wins Head-to-Head Institutional Verdict (2–2 across 6 Pillars · 6–0 Matrix Metrics)
CHEK Overall Winner
6-Pillar Tally: CLSD 2 – 2 CHEK (2 Tie)
Matrix Metrics: CLSD 0 – 6 CHEK
As of Nov 28, 2025, Check-Cap Ltd. (CHEK) is the stronger overall head-to-head candidate over Clearside Biomedical, Inc. (CLSD) in the Tradestie Institutional Equity Comparison Engine, winning 6–0 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality). CLSD carries a Unified Composite Score of 43.3/100 (HOLD) at $0.41 (N/M Forward P/E, -3502.5% operating margin), whereas CHEK carries 52.1/100 (HOLD) at $1.61 (N/M Forward P/E, 0.0% operating margin).
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CLSD vs CHEK. Trailing 12-month operating profitability (CLSD -3502.5% vs CHEK 0.0%) and valuation multiples (CLSD N/M vs CHEK N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Pharmaceutical Preparations value chain with $2.9M market capitalization and -3502.5% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
CHEK Moat ProfileCyclical / Execution-Driven Positioning
X-Ray Apparatus & Tubes & Related Irradiation Apparatus Operator
Competes within the X-Ray Apparatus & Tubes & Related Irradiation Apparatus value chain with $9.2M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ CLSD vs CHEK Key Questions & Quantitative Answers
As of Nov 28, 2025, Check-Cap Ltd. (CHEK) is the stronger overall head-to-head candidate over Clearside Biomedical, Inc. (CLSD) in the Tradestie Institutional Equity Comparison Engine, winning 6–0 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality). CLSD carries a Unified Composite Score of 43.3/100 (HOLD) at $0.41 (N/M Forward P/E, -3502.5% operating margin), whereas CHEK carries 52.1/100 (HOLD) at $1.61 (N/M Forward P/E, 0.0% operating margin). Technically, CLSD sits in a Neutral phase (RSI 17.4, UNCLASSIFIED options structure) and CHEK sits in a Neutral phase (RSI 51.0, UNCLASSIFIED options structure).
CHEK leads the Growth & Scale pillar: CLSD posts -80.6% YoY revenue growth and +0.0% YoY earnings growth on $3.3M TTM revenue (88.1% gross margin, -3502.5% operating margin), compared with CHEK at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, CLSD generates $3.3M in USD-normalized revenue versus N/A for CHEK. In operating R&D and SG&A reinvestment, CLSD deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CHEK.
CLSD screens cheaper on headline valuation multiples. CLSD trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.9x EV/Revenue (unreported EBITDA margin), whereas CHEK trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CLSD (-1310.0% ROE) versus CHEK (-226.2% ROE) capital efficiency.
In options market volatility and institutional positioning, CLSD carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.24β · 269% Vol realized risk). By comparison, CHEK carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.94β · 179% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 28, 2025. For educational research only; not investment advice.